The Craneware Group exec suggests ways to cushion 340B contract pharmacy losses in new Healthcare Business Today article
Lisa Scholz, PharmD, MBA, FACHE, Senior Vice President of Industry Relations for The Craneware Group, has authored a new guide for 340B covered entities struggling with drug manufacturer contract pharmacy restrictions in Healthcare Business Today.
Headlined “As Standoff Over 340B Contract Pharmacies Grinds On, Covered Entities Have Options,” the article outlines some paths covered entities can take to mitigate the financial losses from the drugmakers’ policies. The biggest decision is whether to agree to the manufacturers’ demands to submit claims data, capturing 340B referrals and using in-house hospital pharmacies to serve as contract pharmacies for standalone 340B clinics.
“Covered entities have likely already picked all the remaining low-hanging fruit available for their 340B program — such as adjusting their formularies, increasing the use of biosimilars and utilizing their own specialty pharmacy or home infusion — and will need to be more resourceful in finding ways to make up the losses,” Scholz writes.
Read the full piece at Healthcare Business Today.
You can also schedule a time to meet with Lisa to discuss this topic more.